Zoetis Stock News

The FDA bestows an Orphan Drug Exclusivity to Jazz's (JAZZ) Xywav for treating idiopathic hypersomnia in adults. This is the second Orphan Drug Exclusivity for the drug.

Advanced Micro Devices, Broadcom, the ARKK ETF and Zoetis were our top stock trades for Wednesday. Now, let's take a look at the charts.

Tobacco stocks remain strong buys after the defeat of the U.S. "nicotine tax" proposal and a reassuring update from British American Tobacco. In Payment, Mastercard and Visa each rebounded by more tha

A whale with a lot of money to spend has taken a noticeably bearish stance on Zoetis . Looking at options history for Zoetis (NYSE: ZTS ) we detected 11 strange trades. If we consider the specifics of each trade, it is accurate to state that 45% of the investors opened trades with bullish expectations and 54% with bearish. From the overall spotted trades, 3 are puts, for a total amount of $645,665 and 8, calls, for a total amount of $2,254,063. What''s The Price Target? Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $200.0 to $250.0 for Zoetis over the Full story available on Benzinga.com

Zoetis (NYSE:ZTS) had its price objective hoisted by Citigroup from $184.00 to $232.00 in a report issued on Monday, Price Targets.com reports. They currently have a neutral rating on the stock. A number of other research firms have also recently issued reports on ZTS. Morgan Stanley initiated coverage on shares of Zoetis in a report []

HALF of the UKs Omicron patients have been struck with surprising symptoms, experts have warned. Many of those who have tested positive for the variant are not reporting the classic Covid symptoms. Instead they are suffering with more cold-like responses, which many might mistake for a simple winter bug. The ZOE Covid Symptoms Study App []

The Latest report about the Animal Medicine market provides a detailed evaluation of the business vertical in question, alongside a brief overview of the industry segments. An exceptionally workable estimation of the present industry scenario has been delivered in the

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis will report Q4 and full year 2021 financial results on Tuesday, Feb. 15, 2022.

Ninety One North America Inc. trimmed its stake in shares of Zoetis Inc. (NYSE:ZTS) by 3.8% in the third quarter, Holdings Channel.com reports. The firm owned 16,631 shares of the companys stock after selling 650 shares during the quarter. Ninety One North America Inc.s holdings in Zoetis were worth $3,229,000 at the end of the []

Waldron Private Wealth LLC boosted its position in shares of Zoetis Inc. (NYSE:ZTS) by 2.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 20,213 shares of the companys stock after purchasing an additional 544 shares during the period. Waldron Private Wealth LLCs holdings []

Renewable energy asset developer and operator Vesper Energy announced a new 15-year virtual power purchase agreement with animal health company Zoetis, which will see the company providing 40 MW of renewable energy to the grid, sufficient to power 33% of Zoetis North American operations. Craig Carson, CEO, Vesper Energy, said: Were proud to work with [] The post Zoetis Sources Renewable Energy to Power 33% of North America Operations appeared first on ESG Today .

Animal Growth Promoter Market 2021 A complete explanation of industrial capacity, ever-increasing demand, sales, and future growth possible is included in the market study and also a CAGR % forecasted from 2021 to 2027. The Animal Growth Promoter market report contains